The latest report by IMARC, titled “Cystic Fibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033,“ the global cystic fibrosis market size is witnessing steady growth. Cystic fibrosis (CF) refers to an inherited disorder caused by the mutation of a protein that impairs the transportation of salt and water across the cell membrane. It results in the build-up of thick and sticky mucus that affects multiple organs, such as the lungs, pancreas, liver, and digestive system. Its symptoms include wheezing, persistent cough, shortness of breath, bloating, malnutrition, and recurrent lung infections. CF is diagnosed by various techniques, such as blood and sweat tests, X-rays, computed tomography (CT) scan, genetic testing, and physical examination. Its treatment involves medications, therapies, and lifestyle changes that aid in alleviating symptoms, preventing complications, and improving the overall quality of life.
Global Cystic Fibrosis Market Trends:
The rising prevalence of CF due to genetic mutation is one of the primary factors driving the market growth. In addition to this, growing consumer awareness regarding the benefits of early diagnosis to improve treatment outcomes, slow disease progression, and prevent various future complications, such as lung damage, malnutrition, diabetes, infertility, and osteoporosis, is acting as another growth-inducing factor. Furthermore, the implementation of various government initiatives to spread awareness and provide access to high-quality and specialized care to patients suffering from cystic fibrosis is positively influencing the market growth. Additionally, the introduction of clustered regularly interspaced short palindromic repeats (CRISPR-Cas9) gene editing technology to correct cystic fibrosis transmembrane conductance regulator (CFTR) protein mutation, activate dormant CFTR genes, and develop personalized medicine is providing an impetus to the market growth. Apart from this, the increasing adoption of nanotechnology to improve drug delivery, reduce side effects and allow better visualization of infected organs in imaging tests is creating a positive outlook for the market. Moreover, the recent development of wearable sweat sensors that can diagnose and monitor cystic fibrosis in real-time and aid healthcare professionals in selecting suitable treatments for individual patients is propelling the market growth. Other factors, including rising expenditure capacities of consumers, increasing investment in the research and development (R&D) of advanced therapeutics, and growing consumer preference for oral medications, are anticipated to drive the market growth.
- Region-wise, the market has been classified into the United States, EU5 (Germany, France, the United Kingdom, Italy, and Spain), and Japan. The United States has the largest patient population for cystic fibrosis and also represents the largest market for its treatment among the seven major markets.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for cystic fibrosis.
- The study also offers a thorough overview of the treatment practices for cystic fibrosis, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800